Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The MRC and BBSRC have recently announced their Industrial CASE awards competitions for 2013.

MRC logoThese awards are made to individual projects to be conducted jointly between a University of Oxford PI and an industrial partner and will provide full funding* (fees, maintenance stipend, and research training support grant) for a student for up to 4 years of full time study. They are designed to “provide doctoral students with a first-rate, challenging research training experience, within the context of a mutually beneficial research collaboration between academic and partner organisations in the private, public and civil society sectors.”

BBSRC logoBids will need to be submitted online by the University of Oxford PI using the Je-S system and will need to be approved at both Departmental and Divisional level for submission to the appropriate research council. Please notify both your departmental contact and the Divisional Office in advance if you are intending to submit a bid so that we are aware of which bids we should expect. Some support may be provided to prepare generic statements such as training statements provided this is sought in good time. If you are intending to apply for a studentship, please contact Bob Mahoney (bob.mahoney@medsci.ox.ac.uk) (until 26th June) and Clare Hayes (clare.hayes@medsci.ox.ac.uk) (after June 26th) in the Medical Sciences Divisional Office.

The closing date for both schemes is 4pm on Wednesday 31st July. However, owing to the two stage approval process PIs should submit bids on Je-S by Monday 29th July at the latest.

Please note that the two research councils have slightly different criteria, e.g. the BBSRC requires information on submission rates whereas the MRC does not. If you are considering submitting bids to both research councils please ensure that you read the criteria carefully before preparing your application.

Further details, and applications forms can be found here:

MRC: http://www.mrc.ac.uk/Fundingopportunities/Studentships/IndustrialCASE/MRC004608.

BBSRC: http://www.bbsrc.ac.uk/business/training/industrial-case.aspx.

 * - Note that as these are RCUK schemes normal UK residence eligibility criteria will apply at the recruitment stage.

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.